ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0616

Influence of Colonic Dialysis on the Distribution of Gut Microbiome in CKD Stage 3-5 Patients

Session Information

  • CKD Mechanisms - 1
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Author

  • Xu, Hui, 2. Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, China
Background

Chronic kidney disease (CKD) becomes a major public health challenge given high incidence rates in the world. colonic dialysis (CD) has been used in pre-dialysis CKD patients (CKD3-5) in many hospitals of China because of its advantages of simple operation, low price and few complications. The gut microbiome is a potential cause of CKD progression and serve as a promising therapeutic target. We raise the question that whether CD improve renal function by affecting intestinal microbiome in CKD3-5 patients.

Improving the imbalance of intestinal microbiome is considered a potential therapeutic target to decline chronic kidney disease(CKD) progression. We amied to investigate the influence of colonic dialysis(CD) on the distribution of gut microbiome in CKD3-5 patients.

Methods

We studied gut microbiota in 50 patients with CKD, 25 CD patients, 25 outpatients(OP), and compared to 34 healthy subjects(HS). The gut microbiome composition was analyzed by a 16S ribosomalRNA(16S rRNA ) gene-based sequencing protocol.

Results

we found that there was no significant difference in the richness of intestinal microbiota between CD and HS, but the richness of bacterial in OP decreased significally (HS VS. OP p = 0.002). CD can increase the abundance of some short chain fatty acid(SCFA) producing bacteria and decrease the abundance of some uremic toxin producing bacteria. CD also can increase the abundance of some anaerobic bacteria in intestine. Compared with OP, the profile of intestinal microbiota in CD group and HS group was more similarity.

Conclusion

Our study reveals CD treatment alterings microbiome profile and increases microbiome richnessll in CKD3-5.